>아시아 태평양 렌티바이러스 벡터 시장, 구성 요소별(렌티바이러스 프로모터, 렌티바이러스 퓨전 태그, 렌티바이러스 패키징 시스템, 기타), 유형(제품, 서비스), 세대(4세대, 3세대, 2세대, 1세대), 워크플로(상류 처리, 하류 처리), 전달 방법(체내, 체외), 질병 지표(암, 유전적 질환, 감염성 질환, 수 의학적 질병, 기타), 응용 분야(유전자 치료, 백신학), 최종 사용자(생명공학 회사, 제약 회사, 계약 연구 기관, 계약 개발 및 제조 기관(CDMO), 학술/연구 기관), 국가(일본, 중국, 한국, 인도, 호주, 싱가포르, 태국, 말레이시아, 인도네시아, 필리핀, 기타 아시아 태평양) 산업 동향 및 2028년까지의 예측
시장 분석 및 통찰력 : 아시아 태평양 렌티바이러스 벡터 시장
렌티바이러스 벡터 시장은 2021년에서 2028년까지의 예측 기간 동안 시장 성장을 이룰 것으로 예상됩니다. Data Bridge Market Research는 시장이 2021년에서 2028년까지의 예측 기간 동안 16.1%의 CAGR로 성장하고 있으며 2028년까지 2억 737만 달러에 도달할 것으로 예상한다고 분석했습니다. 렌티바이러스 벡터에 대한 수요 증가와 감염성 질환의 증가는 예측 기간 동안 시장 수요를 촉진한 주요 요인입니다.
렌티바이러스 벡터(LV)는 분열하지 않는 세포와 분열하는 세포에서 관심 유전자를 안정적으로 발현할 수 있는 능력 덕분에 포유류 세포에서 유전자 전달을 위한 효율적인 매개체입니다. 렌티바이러스는 긴 잠복기와 지속적인 감염이 있는 것으로 알려진 인간과 동물 병원체입니다. 초기 감염과 첫 증상이 나타나는 사이의 시간은 몇 개월 또는 몇 년에 이를 수 있습니다.
분자 생물학자들은 종종 바이러스 벡터를 사용하여 유전 물질을 세포로 전달합니다. 이 절차는 생체 내(살아있는 유기체 내부) 또는 세포 배양(시험관 내)에서 수행될 수 있습니다. 바이러스는 감염된 세포 내부로 유전체를 효율적으로 운반하기 위해 특수한 분자 메커니즘을 개발했습니다.
노령 인구의 증가와 이번 코로나19 사태 동안 백신 개발에 대한 수요는 렌티바이러스 벡터 시장의 성장에 효과적으로 도움이 됩니다. 그러나 확장성 부족과 렌티바이러스 벡터의 하류 정제 한계는 렌티바이러스 벡터 시장의 미래 성장을 방해할 수 있습니다. 주요 시장 참여자의 전략적 이니셔티브와 유전체학에 대한 자금 지원 증가는 아시아 태평양 렌티바이러스 벡터 시장 성장의 기회로 작용합니다. 렌티바이러스 벡터 제품과 관련된 엄격한 규제 정책과 부작용은 미래 시장 성장에 대한 과제로 작용합니다.
렌티바이러스 벡터 시장 보고서는 시장 점유율, 새로운 개발 및 제품 파이프라인 분석, 국내 및 지역 시장 참여자의 영향, 새로운 수익 주머니, 시장 규정의 변화, 제품 승인, 전략적 의사 결정, 제품 출시, 지리적 확장 및 시장의 기술 혁신 측면에서의 분석 기회에 대한 세부 정보를 제공합니다. 분석 및 시장 시나리오를 이해하려면 분석가 브리핑을 위해 저희에게 연락하세요. 저희 팀은 원하는 목표를 달성하기 위한 수익 영향 솔루션을 만드는 데 도움을 드릴 것입니다.
아시아 태평양 렌티바이러스 벡터 시장 범위 및 시장 규모
렌티바이러스 벡터 시장은 구성 요소, 유형, 세대, 워크플로, 전달 방법, 질병 표시, 응용 프로그램 및 최종 사용자를 기준으로 하는 8개의 주요 세그먼트로 세분화됩니다. 세그먼트 간의 성장은 틈새 성장 포켓과 시장에 접근하고 핵심 응용 분야와 타겟 시장의 차이점을 파악하기 위한 전략을 분석하는 데 도움이 됩니다.
- 구성 요소를 기준으로 렌티바이러스 벡터 시장은 렌티바이러스 프로모터, 렌티바이러스 퓨전 태그, 렌티바이러스 패키징 시스템 및 기타로 세분화됩니다. 2021년에는 렌티바이러스 패키징 시스템 부문이 중국, 일본 및 아시아 태평양 지역의 다른 국가에서 연구 발전이 증가함에 따라 렌티바이러스 벡터 시장을 지배할 것으로 예상됩니다.
- 유형에 따라 렌티바이러스 벡터 시장은 제품과 서비스로 세분화됩니다. 2021년에는 고령 인구가 많기 때문에 제품 부문이 렌티바이러스 벡터 시장을 지배할 것으로 예상됩니다.
- 세대를 기준으로 렌티바이러스 벡터 시장은 4세대, 3세대, 2세대, 1세대로 세분화됩니다. 2021년에는 4세대 세그먼트가 유전자 치료 응용 프로그램과 관련된 부작용이 적기 때문에 렌티바이러스 벡터 시장을 지배할 것으로 예상됩니다.
- 워크플로우를 기준으로 렌티바이러스 벡터 시장은 상류 처리와 하류 처리로 세분화됩니다. 2021년에는 연구 기관과 제약 회사의 숙련된 인력이 증가함에 따라 상류 처리 부문이 렌티바이러스 벡터 시장을 지배할 것으로 예상됩니다.
- 전달 방식을 기준으로 렌티바이러스 벡터 시장은 생체 내와 생체 외로 세분화됩니다. 2021년에는 바이러스 벡터에 대한 임상 시험 개발이 증가함에 따라 생체 내 세그먼트가 렌티바이러스 벡터 시장을 지배할 것으로 예상됩니다.
- 질병 표시에 따라 렌티바이러스 벡터 시장은 암, 유전적 질환, 감염성 질환, 수의학적 질병 및 기타로 세분화됩니다. 2021년에는 인구가 많고 암 사례가 많기 때문에 암 부문이 렌티바이러스 벡터 시장을 지배할 것으로 예상됩니다.
- 응용 프로그램을 기준으로 렌티바이러스 벡터 시장은 유전자 치료 와 백신학으로 세분화됩니다. 2021년에는 아시아 국가에서 의료 관광이 널리 퍼지면서 유전자 치료 부문이 렌티바이러스 벡터 시장을 지배할 것으로 예상됩니다.
- On the basis of end user, the lentiviral vector market is segmented into biotechnology companies, pharmaceutical companies, contract research organizations, contract development and manufacturing organization (CDMO) and academic/ research institutes. In 2021, academic/ research institutes segment is expected to dominate the lentiviral vector market due to rising government fund for research and development procedures.
Lentiviral Vector Market Country Level Analysis
The lentiviral vector market is analysed and market size information is provided by the country, component, type, generation, workflow, delivery method, disease indication, application and end user as referenced above.
The countries covered in the lentiviral vector market report in this region are China, Japan, Australia, India, South Korea, Singapore, Thailand, Malaysia, Indonesia, Philippines and Rest of Asia-Pacific.
Products segment is dominating in China which is leading in the Asia-Pacific region due to high geriatric population and high vaccine production.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Strategic Initiatives by Manufactures is Creating New Opportunities for Players in the Lentiviral Vector Market
Lentiviral vector market also provides you with detailed market analysis for every country growth. Moreover, it provides detail data regarding growth in lentiviral vector sales, partnership, acquisition, distribution agreement among the market players of Asia-Pacific region. The data is available for historic period 2010 to 2019.
Competitive Landscape and Lentiviral Vector Market Share Analysis
Lentiviral vector market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to lentiviral vector market.
렌티바이러스 벡터를 거래하는 주요 기업으로는 Merck KGaA, FinVector Oy, Oxford Biomedica, Sirion-Biotech GmbH, Thermo Fisher Scientific Inc., Applied Biological Materials Inc., Creative Biolabs, Batavia Biosciences BV, Waisman Biomanufacturing, Cytiva(Danaher의 자회사), bluebird bio, Inc., System Biosciences, LLC, COBRA BIOLOGICS, Takara Bio Inc., OriGene Technologies, Inc., Sino Biological, Inc., Cell Biolabs, Inc., Lonza, GENEMEDI, FUJIFILM Diosynth Biotechnologies(FUJIFILM Holdings Corporation의 자회사) 등이 있습니다. DBMR 분석가는 경쟁 우위를 이해하고 각 경쟁사에 대한 경쟁 분석을 별도로 제공합니다.
또한 전 세계 여러 회사에서 많은 계약과 협정을 체결하면서 렌티바이러스 벡터 시장도 가속화되고 있습니다.
예를 들어,
- 2021년 2월, Thermo Fisher Scientific Inc.는 연례 CMO Leadership Awards에서 6개의 상을 수상했다고 발표했습니다. Life Science Leader와 Outsourced Pharma가 수여하는 상은 바이오제약 및 바이오테크 회사에서 평가한 최고의 계약 제조 파트너를 인정합니다. 이러한 인정을 통해 전 세계적으로 입지를 강화하고 향후 몇 년 동안 성장이 급증할 것으로 예상됩니다.
시장 참여자들의 협업, 제품 출시, 사업 확장, 수상 및 인정, 합작 투자 및 기타 전략을 통해 렌티바이러스 벡터 시장에서 회사의 입지를 강화하고 있으며, 이는 조직의 수익 성장에도 도움이 됩니다.
SKU-
세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요
- 대화형 데이터 분석 대시보드
- 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
- 사용자 정의 및 질의를 위한 리서치 분석가 액세스
- 대화형 대시보드를 통한 경쟁자 분석
- 최신 뉴스, 업데이트 및 추세 분석
- 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
목차
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF ASIA-PACIFIC LENTIVIRAL VECTOR MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 COMPONENT LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 MARKET APPLICATION COVERAGE GRID
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 ADHERENT AND SUSPENSION CULTURES: OVERVIEW
4.2 PRICING OF LENTIVIRAL VECTORS: PRODUCT AND SERVICE
4.2.1 PRODUCT
4.2.2 SERVICES
5 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: REGULATORY FRAMEWORK
5.1 REGULATION IN THE UNITED STATES
5.2 REGULATIONS IN EUROPE
5.3 REGULATIONS IN INDIA
5.4 REGULATIONS IN JAPAN
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISE IN DEMAND FOR VIRAL VECTORS
6.1.2 EMERGENCE OF COVID-19 AND DEMAND FOR VACCINE DEVELOPMENT
6.1.3 BENEFITS OF VIRAL VECTORS FOR GENE THERAPY
6.1.4 RISE IN NUMBER OF INFECTIOUS DISEASES
6.1.5 GROWING GERIATRIC POPULATION
6.2 RESTRAINTS
6.2.1 LACK OF SCALABILITY
6.2.2 LIMITATIONS OF DOWNSTREAM PURIFICATION
6.2.3 SHORTAGE OF SKILLED PERSONNELS
6.3 OPPORTUNITIES
6.3.1 INCREASED HEALTHCARE FACILITY AND FUNDING FOR GENOMICS
6.3.2 RISE IN TECHNOLOGICAL ADVANCEMENT
6.3.3 INCREASE IN DEMAND FOR PERSONALIZED MEDICINES
6.3.4 STRATEGIC INITIATIVES BY KEY MARKET PLAYERS
6.4 CHALLENGES
6.4.1 STRINGENT GOVERNMENT APPROVAL POLICIES
6.4.2 SIDE-EFFECTS ASSOCIATED WITH LENTIVIRAL VECTORS INTEGRATION
7 IMPACT OF COVID-19 ON THE ASIA-PACIFIC LENTIVIRAL VECTOR MARKET
7.1 IMPACT ON PRICE
7.2 IMPACT ON DEMAND
7.3 IMPACT ON SUPPLY CHAIN
7.4 STRATEGIC DECISIONS OF GOVERNMENT AND MANUFACTURERS
7.5 CONCLUSION
8 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY COMPONENT
8.1 OVERVIEW
8.2 LENTIVIRUS PACKAGING SYSTEMS
8.3 LENTIVIRAL PROMOTER
8.3.1 LENTIVIRUS PROMOTER VECTORS
8.3.2 LENTIVIRUS PROMOTERLESS VECTORS
8.4 LENTIVIRAL FUSION TAGS
8.5 OTHERS
9 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY TYPE
9.1 OVERVIEW
9.2 PRODUCT
9.2.1 HUMAN IMMUNODEFICIENCY VIRUS (HIV)
9.2.2 FELINE IMMUNODEFICIENCY VIRUS (FIV)
9.2.3 EQUINE INFECTIOUS ANEMIA VIRUS (EIAV)
9.3 SERVICES
10 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY GENERATION
10.1 OVERVIEW
10.2 4TH GENERATION
10.3 3RD GENERATION
10.4 2ND GENERATION
10.5 1ST GENERATION
11 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY WORKFLOW
11.1 OVERVIEW
11.2 UPSTREAM PROCESSING
11.2.1 VECTOR AMPLIFICATION & EXPANSION
11.2.2 VECTOR RECOVERY/ HARVESTING
11.3 DOWNSTREAM PROCESSING
11.3.1 PURIFICATION
11.3.2 FILL-FINISH
12 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD
12.1 OVERVIEW
12.2 IN-VIVO
12.3 EX-VIVO
13 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION
13.1 OVERVIEW
13.2 CANCER
13.3 GENETIC DISORDERS
13.3.1 B-THALESSEMIA
13.3.2 X-LINKED ADRENO LEUKODYSTROPHY
13.3.3 METACHROMATIC LEUKODYSTROPHY
13.3.4 WISKOTT-ALDRICH SYNDROME
13.3.5 OTHERS
13.4 INFECTIOUS DISEASES
13.4.1 HIV
13.4.2 OTHERS
13.5 VETERINARY DISEASES
13.6 OTHERS
14 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY APPLICATION
14.1 OVERVIEW
14.2 GENE THERAPY
14.2.1 RECOMBINANT PROTEIN EXPRESSION
14.2.2 FUNCTIONAL ASSAYS
14.2.3 IN VITRO TRANSCRIPTION
14.2.4 PROTEIN CHARACTERIZATION
14.2.5 OTHERS
14.3 VACCINOLOGY
15 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY END USER
15.1 OVERVIEW
15.2 ACADEMIC/ RESEARCH INSTITUTES
15.3 PHARMACEUTICAL COMPANIES
15.4 CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS
15.5 BIOTECHNOLOGY COMPANIES
15.6 CONTRACT RESEARCH ORGANIZATIONS
16 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY REGION
16.1 ASIA-PACIFIC
16.1.1 CHINA
16.1.2 JAPAN
16.1.3 AUSTRALIA
16.1.4 INDIA
16.1.5 SOUTH KOREA
16.1.6 SINGAPORE
16.1.7 MALAYSIA
16.1.8 THAILAND
16.1.9 INDONESIA
16.1.10 PHILIPPINES
16.1.11 REST OF ASIA-PACIFIC
17 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
18 SWOT
19 COMPANY PROFILE
19.1 OXFORD BIOMEDICA
19.1.1 COMPANY SNAPSHOT
19.1.2 REVENUE ANALYSIS
19.1.3 COMPANY SHARE ANALYSIS
19.1.4 PRODUCT PORTFOLIO
19.1.5 RECENT DEVELOPMENTS
19.2 THERMO FISHER SCIENTIFIC INC.
19.2.1 COMPANY SNAPSHOT
19.2.2 REVENUE ANALYSIS
19.2.3 COMPANY SHARE ANALYSIS
19.2.4 PRODUCT PORTFOLIO
19.2.5 RECENT DEVELOPMENTS
19.3 MERCK KGAA
19.3.1 COMPANY SNAPSHOT
19.3.2 REVENUE ANALYSIS
19.3.3 COMPANY SHARE ANALYSIS
19.3.4 PRODUCT PORTFOLIO
19.3.5 RECENT DEVELOPMENT
19.4 LONZA
19.4.1 COMPANY SNAPSHOT
19.4.2 RECENT ANALYSIS
19.4.3 COMPANY SHARE ANALYSIS
19.4.4 PRODUCT PORTFOLIO
19.4.5 RECENT DEVELOPMENTS
19.5 CYTIVA (A SUBSIDIARY OF DANAHER)
19.5.1 COMPANY SNAPSHOT
19.5.2 REVENUE ANALYSIS
19.5.3 PRODUCT PORTFOLIO
19.5.4 RECENT DEVELOPMENT
19.6 APPLIED BIOLOGICAL MATERIALS INC.
19.6.1 COMPANY SNAPSHOT
19.6.2 PRODUCT PORTFOLIO
19.6.3 RECENT DEVELOPMENT
19.7 BATAVIA BIOSCIENCES B.V.
19.7.1 COMPANY SNAPSHOT
19.7.2 PRODUCT PORTFOLIO
19.7.3 RECENT DEVELOPMENT
19.8 BLUEBIRD BIO, INC.
19.8.1 COMPANY SNAPSHOT
19.8.2 REVENUE ANALYSIS
19.8.3 PRODUCT PORTFOLIO
19.8.4 RECENT DEVELOPMENTS
19.9 CELL BIOLABS, INC.
19.9.1 COMPANY SNAPSHOT
19.9.2 PRODUCT PORTFOLIO
19.9.3 RECENT DEVELOPMENT
19.1 CREATIVE BIOLABS
19.10.1 COMPANY SNAPSHOT
19.10.2 SERVICE PORTFOLIO
19.10.3 RECENT DEVELOPMENT
19.11 COBRA BIOLOGICS LIMITED
19.11.1 COMPANY SNAPSHOT
19.11.2 PRODUCT PORTFOLIO
19.11.3 RECENT DEVELOPMENTS
19.12 FINVECTOR OY
19.12.1 COMPANY SNAPSHOT
19.12.2 SERVICE PORTFOLIO
19.12.3 RECENT DEVELOPMENT
19.13 FUJIFIM DIOSYNTH BIOTECHNOLOGIES (A SUBSIDIARY OF FUJIFILM HOLDINGS CORPORATION)
19.13.1 COMPANY SNAPSHOT
19.13.2 RECENT ANALYSIS
19.13.3 SERVICE PORTFOLIO
19.13.4 RECENT DEVELOPMENTS
19.14 GENEMEDI
19.14.1 COMPANY SNAPSHOT
19.14.2 PRODUCT PORTFOLIO
19.14.3 RECENT DEVELOPMENT
19.15 ORIGENE TECHNOLOGIES, INC.
19.15.1 COMPANY SNAPSHOT
19.15.2 PRODUCT PORTFOLIO
19.15.3 RECENT DEVELOPMENTS
19.16 SINO BIOLOGICAL, INC.
19.16.1 COMPANY SNAPSHOT
19.16.2 PRODUCT PORTFOLIO
19.16.3 RECENT DEVELOPMENT
19.17 SIRION-BIOTECH GMBH
19.17.1 COMPANY SNAPSHOT
19.17.2 PRODUCT PORTFOLIO
19.17.3 RECENT DEVELOPMENTS
19.18 SYSTEM BIOSCIENCES, LLC
19.18.1 COMPANY SNAPSHOT
19.18.2 PRODUCT PORTFOLIO
19.18.3 RECENT DEVELOPMENTS
19.19 TAKARA BIO INC.
19.19.1 COMPANY SNAPSHOT
19.19.2 RECENT ANALYSIS
19.19.3 PRODUCT PORTFOLIO
19.19.4 RECENT DEVELOPMENTS
19.2 WAISMAN BIOMANUFACTURING
19.20.1 COMPANY SNAPSHOT
19.20.2 PRODUCT PORTFOLIO
19.20.3 RECENT DEVELOPMENTS
20 QUESTIONNAIRE
21 RELATED REPORTS
표 목록
TABLE 1 THERMO FISHER SCIENTIFIC
TABLE 2 THE REGENTS OF THE UNIVERSITY OF MICHIGAN
TABLE 3 KERAFAST
TABLE 4 APPLIED BIOLOGICAL MATERIALS INC.
TABLE 5 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 6 ASIA-PACIFIC LENTIVIRUS PACKAGING SYSTEMS IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 7 ASIA-PACIFIC LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 8 ASIA-PACIFIC LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 9 ASIA-PACIFIC LENTIVIRAL FUSION TAGS IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 10 ASIA-PACIFIC OTHERS IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 11 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 12 ASIA-PACIFIC PRODUCT IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 13 ASIA-PACIFIC PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 14 ASIA-PACIFIC SERVICES IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 15 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)
TABLE 16 ASIA-PACIFIC 4TH-GENERATION IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 17 ASIA-PACIFIC 3RD-GENERATION IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 18 ASIA-PACIFIC 2ND-GENERATION IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 19 ASIA-PACIFIC 1ST-GENERATION IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 20 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY WORK FLOW, 2019-2028 (USD MILLION)
TABLE 21 ASIA-PACIFIC UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 22 ASIA-PACIFIC UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 23 ASIA-PACIFIC DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 24 ASIA-PACIFIC DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 25 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)
TABLE 26 ASIA-PACIFIC IN-VIVO IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 27 ASIA-PACIFIC EX-VIVO IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 28 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)
TABLE 29 ASIA-PACIFIC CANCER IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 30 ASIA-PACIFIC GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 31 ASIA-PACIFIC GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 32 ASIA-PACIFIC INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 33 ASIA-PACIFIC INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 34 ASIA-PACIFIC VETERINARY DISEASES IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 35 ASIA-PACIFIC OTHERS IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 36 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 37 ASIA-PACIFIC GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 38 ASIA-PACIFIC GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 39 ASIA-PACIFIC VACCINOLOGY IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 40 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 41 ASIA-PACIFIC ACADEMIC/ RESEARCH INSTITUTES IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 42 ASIA-PACIFIC PHARMACEUTICAL COMPANIES IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 43 ASIA-PACIFIC CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 44 ASIA-PACIFIC BIOTECHNOLOGY COMPANIES IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 45 ASIA-PACIFIC CONTRACT RESEARCH ORGANIZATIONS IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 46 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 47 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 48 ASIA-PACIFIC LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 49 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 50 ASIA-PACIFIC PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 51 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)
TABLE 52 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)
TABLE 53 ASIA-PACIFIC UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 54 ASIA-PACIFIC DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 55 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)
TABLE 56 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)
TABLE 57 ASIA-PACIFIC GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 58 ASIA-PACIFIC INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 59 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 60 ASIA-PACIFIC GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 61 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 62 CHINA LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 63 CHINA LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 64 CHINA LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 65 CHINA PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 66 CHINA LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)
TABLE 67 CHINA LENTIVIRAL VECTOR MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)
TABLE 68 CHINA UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 69 CHINA DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 70 CHINA LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)
TABLE 71 CHINA LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)
TABLE 72 CHINA GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 73 CHINA INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 74 CHINA LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 75 CHINA GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 76 CHINA LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 77 JAPAN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 78 JAPAN LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 79 JAPAN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 80 JAPAN PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 81 JAPAN LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)
TABLE 82 JAPAN LENTIVIRAL VECTOR MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)
TABLE 83 JAPAN UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 84 JAPAN DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 85 JAPAN LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)
TABLE 86 JAPAN LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)
TABLE 87 JAPAN GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 88 JAPAN INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 89 JAPAN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 90 JAPAN GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 91 JAPAN LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 92 AUSTRALIA LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 93 AUSTRALIA LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 94 AUSTRALIA LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 95 AUSTRALIA PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 96 AUSTRALIA LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)
TABLE 97 AUSTRALIA LENTIVIRAL VECTOR MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)
TABLE 98 AUSTRALIA UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 99 AUSTRALIA DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 100 AUSTRALIA LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)
TABLE 101 AUSTRALIA LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)
TABLE 102 AUSTRALIA GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 103 AUSTRALIA INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 104 AUSTRALIA LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 105 AUSTRALIA GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 106 AUSTRALIA LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 107 INDIA LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 108 INDIA LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 109 INDIA LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 110 INDIA PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 111 INDIA LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)
TABLE 112 INDIA LENTIVIRAL VECTOR MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)
TABLE 113 INDIA UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 114 INDIA DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 115 INDIA LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)
TABLE 116 INDIA LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)
TABLE 117 INDIA GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 118 INDIA INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 119 INDIA LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 120 INDIA GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 121 INDIA LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 122 SOUTH KOREA LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 123 SOUTH KOREA LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 124 SOUTH KOREA LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 125 SOUTH KOREA PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 126 SOUTH KOREA LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)
TABLE 127 SOUTH KOREA LENTIVIRAL VECTOR MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)
TABLE 128 SOUTH KOREA UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 129 SOUTH KOREA DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 130 SOUTH KOREA LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)
TABLE 131 SOUTH KOREA LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)
TABLE 132 SOUTH KOREA GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 133 SOUTH KOREA INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 134 SOUTH KOREA LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 135 SOUTH KOREA GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 136 SOUTH KOREA LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 137 SINGAPORE LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 138 SINGAPORE LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 139 SINGAPORE LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 140 SINGAPORE PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 141 SINGAPORE LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)
TABLE 142 SINGAPORE LENTIVIRAL VECTOR MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)
TABLE 143 SINGAPORE UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 144 SINGAPORE DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 145 SINGAPORE LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)
TABLE 146 SINGAPORE LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)
TABLE 147 SINGAPORE GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 148 SINGAPORE INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 149 SINGAPORE LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 150 SINGAPORE GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 151 SINGAPORE LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 152 MALAYSIA LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 153 MALAYSIA LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 154 MALAYSIA LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 155 MALAYSIA PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 156 MALAYSIA LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)
TABLE 157 MALAYSIA LENTIVIRAL VECTOR MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)
TABLE 158 MALAYSIA UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 159 MALAYSIA DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 160 MALAYSIA LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)
TABLE 161 MALAYSIA LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)
TABLE 162 MALAYSIA GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 163 MALAYSIA INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 164 MALAYSIA LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 165 MALAYSIA GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 166 MALAYSIA LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 167 THAILAND LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 168 THAILAND LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 169 THAILAND LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 170 THAILAND PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 171 THAILAND LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)
TABLE 172 THAILAND LENTIVIRAL VECTOR MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)
TABLE 173 THAILAND UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 174 THAILAND DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 175 THAILAND LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)
TABLE 176 THAILAND LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)
TABLE 177 THAILAND GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 178 THAILAND INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 179 THAILAND LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 180 THAILAND GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 181 THAILAND LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 182 INDONESIA LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 183 INDONESIA LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 184 INDONESIA LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 185 INDONESIA PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 186 INDONESIA LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)
TABLE 187 INDONESIA LENTIVIRAL VECTOR MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)
TABLE 188 INDONESIA UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 189 INDONESIA DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 190 INDONESIA LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)
TABLE 191 INDONESIA LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)
TABLE 192 INDONESIA GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 193 INDONESIA INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 194 INDONESIA LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 195 INDONESIA GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 196 INDONESIA LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 197 PHILIPPINES LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 198 PHILIPPINES LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 199 PHILIPPINES LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 200 PHILIPPINES PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 201 PHILIPPINES LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)
TABLE 202 PHILIPPINES LENTIVIRAL VECTOR MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)
TABLE 203 PHILIPPINES UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 204 PHILIPPINES DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 205 PHILIPPINES LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)
TABLE 206 PHILIPPINES LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)
TABLE 207 PHILIPPINES GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 208 PHILIPPINES INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 209 PHILIPPINES LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 210 PHILIPPINES GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 211 PHILIPPINES LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 212 REST OF ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
그림 목록
FIGURE 1 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: SEGMENTATION
FIGURE 2 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: DATA TRIANGULATION
FIGURE 3 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: DROC ANALYSIS
FIGURE 4 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: ASIA-PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: MULTIVARIATE MODELLING
FIGURE 7 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: DBMR MARKET POSITION GRID
FIGURE 9 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 11 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: SEGMENTATION
FIGURE 12 GROWING GERIATRIC POPULATION IS EXPECTED TO DRIVE THE ASIA-PACIFIC LENTIVIRAL VECTOR MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 13 LENTIVIRUS PACKAGING SYSTEMS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC LENTIVIRAL VECTOR MARKET IN 2021 & 2028
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF ASIA-PACIFIC LENTIVIRAL VECTOR MARKET
FIGURE 15 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY COMPONENT, 2020
FIGURE 16 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY COMPONENT, 2019-2028 (USD MILLION)
FIGURE 17 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY COMPONENT, CAGR (2021-2028)
FIGURE 18 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY COMPONENT, LIFELINE CURVE
FIGURE 19 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY TYPE, 2020
FIGURE 20 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY TYPE, 2019-2028 (USD MILLION)
FIGURE 21 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY TYPE, CAGR (2021-2028)
FIGURE 22 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY TYPE, LIFELINE CURVE
FIGURE 23 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY GENERATION, 2020
FIGURE 24 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY GENERATION, 2019-2028 (USD MILLION)
FIGURE 25 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY GENERATION, CAGR (2021-2028)
FIGURE 26 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY GENERATION, LIFELINE CURVE
FIGURE 27 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY WORK FLOW, 2020
FIGURE 28 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY WORK FLOW, 2019-2028 (USD MILLION)
FIGURE 29 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY WORK FLOW, CAGR (2021-2028)
FIGURE 30 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY WORK FLOW, LIFELINE CURVE
FIGURE 31 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY DELIVERY METHOD, 2020
FIGURE 32 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY DELIVERY METHOD, 2019-2028 (USD MILLION)
FIGURE 33 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY DELIVERY METHOD, CAGR (2021-2028)
FIGURE 34 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY DELIVERY METHOD, LIFELINE CURVE
FIGURE 35 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY DISEASE INDICATION, 2020
FIGURE 36 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY DISEASE INDICATION, 2019-2028 (USD MILLION)
FIGURE 37 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY DISEASE INDICATION, CAGR (2021-2028)
FIGURE 38 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY DISEASE INDICATION, LIFELINE CURVE
FIGURE 39 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY APPLICATION, 2020
FIGURE 40 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY APPLICATION, 2019-2028 (USD MILLION)
FIGURE 41 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY APPLICATION, CAGR (2021-2028)
FIGURE 42 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 43 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY END USER, 2020
FIGURE 44 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY END USER, 2019-2028 (USD MILLION)
FIGURE 45 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY END USER, CAGR (2021-2028)
FIGURE 46 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY END USER, LIFELINE CURVE
FIGURE 47 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: SNAPSHOT (2020)
FIGURE 48 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY COUNTRY (2020)
FIGURE 49 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY COUNTRY (2021 & 2028)
FIGURE 50 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY COUNTRY (2020 & 2028)
FIGURE 51 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY COMPONENT (2021-2028)
FIGURE 52 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: COMPANY SHARE 2020 (%)
연구 방법론
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.
DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.
사용자 정의 가능
Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.
